| James P O'connor, MD | |
|
1213 E Clay St, Richmond, VA 23298-5071 | |
| (804) 828-9084 | |
| (804) 828-8991 |
| Full Name | James P O'connor |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 12 Years |
| Location | 1213 E Clay St, Richmond, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760743165 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 0101266827 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical College Of Virginia Hospitals | Richmond, VA | Hospital |
| Riverside Tappahannock Hospital | Tappahannock, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcv Associated Physicians | 4385542117 | 1312 |
News Archive
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.
The July 2012 issue of Health Affairs, published Monday, examines the impact of PEPFAR, focusing on "the origins of the program; the lessons learned from implementation; the successes achieved in terms of human health and well-being; and the opportunities that now exist to lay the groundwork for an 'AIDS-free generation,'" the Health Affairs Blog reports, noting, "The new Health Affairs issue will be discussed Tuesday morning at a Washington, D.C., briefing."
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
A new analysis reveals that more than 90,000 new cancer cases a year in the United States may be due to physical inactivity and prolonged periods of sitting. The researchers presented their findings at the annual conference of the American Institute for Cancer Research (AICR) in Washington, D.C., citing about 49,000 cases of breast cancer and 43,000 of colon cancer from over 200 studies worldwide.
› Verified 9 days ago
| Entity Name | Mcv Associated Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710959457 PECOS PAC ID: 4385542117 Enrollment ID: O20031230000559 |
News Archive
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.
The July 2012 issue of Health Affairs, published Monday, examines the impact of PEPFAR, focusing on "the origins of the program; the lessons learned from implementation; the successes achieved in terms of human health and well-being; and the opportunities that now exist to lay the groundwork for an 'AIDS-free generation,'" the Health Affairs Blog reports, noting, "The new Health Affairs issue will be discussed Tuesday morning at a Washington, D.C., briefing."
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
A new analysis reveals that more than 90,000 new cancer cases a year in the United States may be due to physical inactivity and prolonged periods of sitting. The researchers presented their findings at the annual conference of the American Institute for Cancer Research (AICR) in Washington, D.C., citing about 49,000 cases of breast cancer and 43,000 of colon cancer from over 200 studies worldwide.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James P O'connor, MD Po Box 91734, Richmond, VA 23291-1734 Ph: (804) 358-6100 | James P O'connor, MD 1213 E Clay St, Richmond, VA 23298-5071 Ph: (804) 828-9084 |
News Archive
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.
The July 2012 issue of Health Affairs, published Monday, examines the impact of PEPFAR, focusing on "the origins of the program; the lessons learned from implementation; the successes achieved in terms of human health and well-being; and the opportunities that now exist to lay the groundwork for an 'AIDS-free generation,'" the Health Affairs Blog reports, noting, "The new Health Affairs issue will be discussed Tuesday morning at a Washington, D.C., briefing."
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
A new analysis reveals that more than 90,000 new cancer cases a year in the United States may be due to physical inactivity and prolonged periods of sitting. The researchers presented their findings at the annual conference of the American Institute for Cancer Research (AICR) in Washington, D.C., citing about 49,000 cases of breast cancer and 43,000 of colon cancer from over 200 studies worldwide.
› Verified 9 days ago
Dr. Amy Samantha May Paul, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1250 E Marshall St, Dept. Of Internal Medicine/geriatric Medicine, Richmond, VA 23298 Phone: 804-254-3500 Fax: 804-254-1616 | |
Dr. Clifton Linwood Parker, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 8300 Fulham Drive, Richmond, VA 23227 Phone: 804-264-5901 | |
Dr. Michael A Mistretta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6600 W Broad St Ste 300, Richmond, VA 23230 Phone: 804-320-4243 Fax: 804-622-0552 | |
Patricia J Sime, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 9000 Stony Point Pkwy, Richmond, VA 23235 Phone: 804-560-8921 Fax: 804-560-8992 | |
Dr. Katherine Lavan Smallwood, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6900 Forest Ave, Suite 300, Richmond, VA 23230 Phone: 804-346-1515 Fax: 804-270-2888 | |
Walid G. Abou Assi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7605 Forest Ave, Suite 109, Richmond, VA 23229 Phone: 804-285-6390 Fax: 804-285-6393 | |
Dr. Paulina Essah, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 719 N 25th St, Richmond, VA 23223 Phone: 804-253-1963 Fax: 804-780-0862 |